Stocks and Investing Stocks and Investing
Wed, April 1, 2020
Tue, March 31, 2020

Difei Yang Initiated (SRPT) at Strong Buy and Held Target at $183 on, Mar 31st, 2020


Published on 2024-10-27 01:35:30 - WOPRAI, Difei Yang
  Print publication without navigation


Difei Yang of Mizuho, Initiated "Sarepta Therapeutics, Inc." (SRPT) at Strong Buy and Held Target at $183 on, Mar 31st, 2020.

Difei has made no other calls on SRPT in the last 4 months.



There are 7 other peers that have a rating on SRPT. Out of the 7 peers that are also analyzing SRPT, 0 agree with Difei's Rating of Hold.



These are the ratings of the 7 analyists that currently disagree with Difei


  • Tazeen Ahmad of "B of A Securities" Maintained at Strong Buy and Held Target at $180 on, Friday, March 27th, 2020
  • Anupam Rama of "JP Morgan" Maintained at Buy with Decreased Target to $160 on, Friday, February 28th, 2020
  • Alethia Young of "Cantor Fitzgerald" Reiterated at Buy with Increased Target to $217 on, Thursday, February 27th, 2020
  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $173 on, Tuesday, December 24th, 2019
  • Brian Abrahams of "RBC Capital" Maintained at Buy with Decreased Target to $200 on, Monday, December 23rd, 2019
  • Brian Skorney of "Baird" Maintained at Buy with Increased Target to $192 on, Friday, December 20th, 2019
  • Yun Zhong of "Janney Montgomery Scott" Maintained at Strong Buy with Increased Target to $175 on, Friday, December 13th, 2019
Contributing Sources